Variant
FLT3 D835 & I836
CI-VAR-00000571Explore in graph →CIViC 3231
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24737502
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Acute Myeloid Leukemia1 | ||||||||
| FLT3 D835 & I836 | FLT3/ABL/Aurora Kinase Inhibitor KW-2449 + Lestaurtinib + Quizartinib + SorafenibSubstitutes | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID8925In this study, records of 69 FLT3 mutated AML patients treated with different FLT3 inhibitors were analyzed for emergence of new mutations. Before the start of therapy with a FLT3 inhibitor, 60 (87%) … (full text at CIViC) PMID 24737502 · Alvarado et al., 2014 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.